Sanofi’s move for Dren Bio’s clinical asset boosts its immunology-focused strategy of becoming a leader in the field.

MC: It is a multidimensional objective that gathers several aspects of Sanofi values and DNA. For Sanofi it is a social responsibility to participate in order to enrich its neighbouring innovation ...

the French pharma company placed an enterprise value of €16bn ($17bn) on Opella, around 14 times the estimated core earnings (EBITDA) for 2024. The decision to divest Opella is part of Sanofi ...

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines.

Sanofi is set to acquire DR-0201 from Dren Bio for up to $1.9 billion, aiming to expand its autoimmune disease pipeline with ...

The deal is the latest in a series of Sanofi investments in its immunology portfolio. According to Sanfoi, DR-0201 can ...

Under the terms of the merger agreement, Sanofi will acquire DR-0201 through the acquisition of the Dren Bio affiliate ...

Sanofi first entered into negotiations with CD&R for the potential sale in October 2024. Bloomberg, at the time, had reported the deal value to be around EUR 15B, or $16.4B. Headquartered in ...

Sanofi has added to its rare disease pipeline ... of $30 million and possible future payments that could drive the total value up to $400 million – will combine miRecule's RNA expertise with ...